Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 13/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11965104 | 0.79 | CYP1A2 (0.51) | CYP11B2CYP19A1 | |
| SCHEMBL11965071 | 0.70 | CYP1A2 (0.50) | CYP11B2CYP19A1CYP11B1SRD5A1 | |
| SCHEMBL7665011 | 0.68 | PARP10 (0.46) | CYP11B2CYP19A1CYP11B1SRD5A1 | |
| SCHEMBL8252930 | 0.65 | CYP11B2 (0.45) | CYP11B2CYP19A1CYP11B1SRD5A1 | |
| SCHEMBL1009901 | 0.64 | MAOA (0.50) | CYP11B2CYP19A1CYP11B1SRD5A1MAPK10 | |
| SCHEMBL23110014 | 0.64 | NOTUM (0.47) | — | |
| SCHEMBL25501701 | 0.64 | CYP11B1 (0.42) | CYP11B2CYP19A1CYP11B1SRD5A1DHODH | |
| SCHEMBL3369293 | 0.63 | CYP11B2 (0.46) | CYP11B2CYP19A1CYP11B1SRD5A1 | |
| SCHEMBL13849161 | 0.63 | CYP11B2 (0.46) | CYP11B2CYP19A1CYP11B1SRD5A1 | |
| SCHEMBL3372953 | 0.63 | SRD5A1 (0.54) | CYP11B2CYP19A1CYP11B1SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202794-A1 | COMPOUNDS | HAVCR2, MAVS, GOT2 | CYP11B2 394/4885CYP19A1 2023/4885CYP11B1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.